Lilly Races to Become First Longevity Big Pharma
Eli Lilly has signed a deal with AI‑focused biotech Insilico Medicine valued up to $2.75 billion, with $115 million paid upfront and the remainder tied to milestones. The agreement grants Lilly an exclusive worldwide license to several preclinical oral candidates and access to Insilico’s generative‑AI platform for future discovery. The partnership extends Lilly’s obesity and metabolic disease franchise and marks a broader push to embed AI into its pipeline, complementing recent collaborations with Innovent and Fauna Bio. Analysts view the move as a step toward positioning Lilly as a longevity‑focused Big Pharma, using AI to accelerate aging‑related therapeutics.
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
Kardigan reported that its experimental hypertension drug tonlamarsen achieved a 67% average reduction in the angiotensinogen biomarker after five monthly doses, confirming target engagement. However, the Phase 2 trial showed no statistically significant difference in office systolic blood pressure between the...
Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug
The FDA approved a high‑dose formulation of Biogen’s SMA drug Spinraza, cutting the loading phase from four to two injections and adding a four‑month maintenance schedule. The new regimen, backed by the DEVOTE study, showed significant motor‑skill gains versus sham...
Triple Therapy Momentum: Caterina Brindicci of AstraZeneca on Breztri in Asthma
AstraZeneca is testing its COPD triple‑inhaler Breztri Aerosphere in uncontrolled asthma. Phase III KALOS and LOGOS trials showed 76‑90 mL improvements in FEV₁ and a 14% reduction in severe exacerbations versus standard ICS/LABA therapy. The studies enrolled about 4,300 patients across 20...
Examining the Architecture of Next-Gen Biotherapeutic Modalities
BioPharm Drug Digest will host a free webinar on April 17, 2026, exploring how the biopharma sector is redesigning antibodies, RNA therapies, and cell therapies with multifunctional architectures. The session highlights programmable biology, next‑generation delivery platforms, and digitized biology models...
Zongertinib a ‘Breakthrough’ for NSCLC with HER2 Mutations
Zongertinib (Hernexeos) received FDA accelerated approval for first‑line treatment of HER2‑mutant advanced NSCLC, based on Beamion LUNG‑1 data presented at the European Lung Cancer Congress. In previously untreated patients (cohort 2), the drug achieved a 76% objective response rate and a...
UK Biotech Day 2026 | May 27-28 | London, UK
UK Biotech Day 2026 will take place on May 27‑28 at the Radisson Hotel & Conference Centre London Heathrow. The two‑day conference convenes executives, R&D scientists, investors, legal and finance professionals from pharma, biotech, medtech, and tech‑bio sectors. Positioned as...
The Likely Evolution of Generic Players in the U.S. Life Sciences Market
The U.S. generic drug market, long driven by the Hatch‑Waxman Act, now supplies about 90% of prescriptions but only 10% of drug spend. Price erosion of 70‑80% within two years and the entry of six to eight competitors have turned...
US FDA Approves Higher-Dose of Biogen’s Genetic Disorder Drug
The U.S. FDA has approved a higher‑dose version of Biogen’s gene‑replacement therapy for a rare genetic muscle‑weakening disorder, likely spinal muscular atrophy. The new regimen starts with two 50 mg loading doses two weeks apart, followed by a 28 mg maintenance dose...
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
Unicycive Therapeutics reported FY 2025 results, highlighting the FDA’s acceptance of its oxylanthanum carbonate (OLC) New Drug Application resubmission with a PDUFA target date of June 29 2026. The company is preparing commercial operations for a potential Q3 2026 launch, while its cash balance...
Something of a Shopping Spree: Novartis to Acquire US-Based Excellergy for up to $2bn
Novartis announced a deal to acquire California‑based Excellergy for up to $2 bn, securing the Phase I antibody Exl‑111 that targets both free and cell‑bound IgE. The acquisition bolsters Novartis’ allergy pipeline, positioning the drug as a next‑generation complement to its existing...
Insilico, Tenacia Expand AI-Driven CNS Collaboration
Insilico Medicine and Tenacia Biotechnology have broadened their AI‑driven collaboration to create additional small‑molecule therapies for central nervous system disorders. Building on a March 2025 program that combined Insilico’s Pharma.AI platform with Tenacia’s proprietary data, the partners will use generative...
New AI Research Reshapes Neuroprotective Drug Discovery Funding
BCC Research’s new Pulse report, “AI Impact on Neuroprotective Agents,” outlines how artificial intelligence is reshaping the discovery, development, and delivery of neuroprotective therapies. The study projects a 4.5% CAGR for the North American market through 2030 and documents hundreds...
Scalable Biotech Manufacturing Targets $14B Cell Therapy Market
Research forecasts the global cell‑therapy manufacturing market to exceed $7 billion in 2026 and reach $14 billion by 2035. The FDA has introduced new manufacturing flexibility to accelerate approval timelines for cell and gene therapies, addressing a capacity bottleneck that analysts expect...
ADHD Medication in Short Supply in Japan as Demand Soars
Japan is experiencing a nationwide shortage of Concerta, the primary stimulant used to treat adult ADHD, as demand surges. The shortage, first noted in late 2023, persists despite Janssen Pharmaceutical’s promise of a two‑month fix, with officials now estimating several...
Europe’s Pivotal Choice: Vaccination Is Health Security
Europe is positioning vaccination as a strategic asset, linking political will, science, and capital to secure health and economic resilience. The European Commission has pledged €225 million to fast‑track next‑generation flu vaccines, including the NOFLU consortium’s mRNA mucosal candidate. By integrating...
10 European Startups to Watch in 2026
A curated list of ten European biotech startups founded since 2021 showcases rapid progress toward clinical milestones and sizable financing. Companies such as Isomorphic Labs, Draig Therapeutics and Adcytherix are moving from platform development to first‑in‑human trials, backed by funding...
AEON Biopharma Inc (AEON) Q4 2025 Earnings Call Transcript
Abeona Therapeutics reported 2025 results highlighting the commercial launch of ZevaSkin, its first autologous cell‑based gene therapy for recessive dystrophic epidermolysis bullosa. Total revenue reached $5.8 million, driven by $2.4 million product sales and a $1.5 billion gain from selling a priority‑review voucher,...
DeFi Development Corp (DFDV) Q4 2025 Earnings Call Transcript
Definium Therapeutics reported that its lead psychedelic candidate DT120 ODT is on track for three pivotal Phase III readouts in 2026. The EMERGE MDD study is fully enrolled with top‑line data expected in late Q2, while the VOYAGE GAD trial...
Unicycive Therapeutics Inc (UNCY) Q4 2025 Earnings Call Transcript
Unicycive Therapeutics reported a 40% revenue drop to $16.1 million for 2025, primarily from lost collaboration and contract manufacturing income, while license revenue modestly rose. R&D spending slipped slightly to $140.7 million, but SG&A surged $12.8 million as the company ramps up...
Guided Therapeutics Inc (GTHP) Q4 2025 Earnings Call Transcript
G1 Therapeutics announced FDA approval of COSELA, a first‑in‑class therapy that reduces chemotherapy‑induced myelosuppression in extensive‑stage small cell lung cancer. The company began commercial launch in early February 2021, reporting rising physician awareness and positive payer feedback. It also outlined...
INmune Bio Inc (INMB) Q4 2025 Earnings Call Transcript
INmune Bio announced the first patient dosing in its phase‑2 XPro trial targeting neuroinflammation‑driven Alzheimer’s disease and outlined parallel phase‑2 studies in mild AD and MCI that leverage biomarker‑guided endpoints. The company also detailed a six‑week phase‑2 trial for treatment‑resistant...
USA Rare Earth Inc (USAR) Q4 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical reported 2025 revenue of $673 million, a 20% year‑over‑year increase that topped the upper end of guidance. The company announced a 10% workforce reduction to streamline costs and focus on near‑term value drivers. Pipeline highlights include resubmission of...
Lexeo Therapeutics Inc (LXEO) Q4 2025 Earnings Call Transcript
Exelixis reported record cabozantinib franchise revenue of $2.12 billion in the U.S. and $2.89 billion globally for 2025, a 17% year‑over‑year increase. Total Q4 2025 revenue reached $599 million, driven by $546.6 million from cabozantinib net product sales and $52.8 million in partner royalties. The...
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Transcript
RenovoRx reported Q4 2025 revenue of $266,000, bringing year‑to‑date sales to roughly $900,000 as it expands the RenovoCath platform across 14 approved cancer centers, up from five earlier in the year. The company ended the quarter with over $10 million in...
Kailera Plans IPO for Phase 3 Obesity Drug From Hengrui
Kailera Therapeutics, one of biotech’s best‑funded startups, announced plans to go public to finance the Phase 3 trial of its obesity drug co‑developed with China’s Hengrui. The IPO aims to raise capital that will position the company against heavyweight rivals such...
Li Ka-Shing’s CK Life Unit Eyes China Fast Track for Cancer Vaccine Pipeline
CK Life Sciences, the Li Ka‑shing‑backed unit, has created Sequencio Therapeutics in Hong Kong to fast‑track its cancer‑vaccine pipeline in mainland China using investigator‑initiated trials (IITs). The fast‑track channel can cut trial start‑up time from 18‑24 months to a few months,...
SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF
The SPIRIT‑HF trial, designed to test spironolactone in heart‑failure patients with preserved or mildly reduced ejection fraction, enrolled only 730 of the planned 1,564 participants and therefore lacked statistical power. Over two years, the composite of cardiovascular death or total...
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
Allogene Therapeutics announced that its lead CAR‑T candidate cemacabtagene ansegedleucel (cema‑cel) stays on track in the pivotal Phase 2 ALPHA3 trial for first‑line consolidation in large B‑cell lymphoma, enrolling over 60 sites globally. An interim futility analysis is slated for April 2026...
![[Articles] Aspirin versus Clopidogrel for Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: 10-Year Follow-Up of the HOST-EXAM Trial](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/f4390aa942546562889e73ef6cd4e624.webp)
[Articles] Aspirin versus Clopidogrel for Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: 10-Year Follow-Up of the HOST-EXAM Trial
Ten‑year extended follow‑up of the HOST‑EXAM trial compared clopidogrel 75 mg daily with aspirin 100 mg daily as chronic monotherapy after PCI. Among 5,438 patients, clopidogrel achieved a 25.4% incidence of the composite of death, MI, stroke, ACS readmission, or major bleeding...
![[Comment] Moving Beyond Aspirin After Percutaneous Coronary Intervention: 10-Year Results From the HOST-EXAM Trial](https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/8acb026fc2949304b649926f35a196b8.webp)
[Comment] Moving Beyond Aspirin After Percutaneous Coronary Intervention: 10-Year Results From the HOST-EXAM Trial
The HOST-EXAM trial, with ten-year follow‑up, compared clopidogrel monotherapy to aspirin after percutaneous coronary intervention. Results showed clopidogrel achieved lower rates of major adverse cardiovascular events and major bleeding. The study enrolled over 5,000 patients from diverse centers, reinforcing the...
#ACC26: Merck Leans Toward Lower Winrevair Dose in Phase 3 Trial for Rare Form of Heart Failure
Merck announced that its experimental drug Winrevair will move into a pivotal Phase 3 trial for a rare form of heart failure, focusing on the lowest dose tested in Phase 2. The Phase 2 data showed a "pretty profound" efficacy signal at that...
Tralokinumab Shows Strong Real-World Efficacy in Atopic Dermatitis for Patients With Skin of Color: April Armstrong, MD, MPH
At the American Academy of Dermatology 2026 meeting, researchers presented TRACE, a real‑world study of tralokinumab in atopic dermatitis. The trial enrolled over 800 patients, with roughly 16% representing skin‑of‑color individuals (Fitzpatrick types 4‑6). After 12 months, 80% of this subgroup achieved...
New Advances in Diabetes Drugs Are Transforming Treatment of Liver Disease
Emerging diabetes therapies are reshaping treatment of metabolic dysfunction‑associated steatotic liver disease (MASLD), especially its severe form MASH. GLP‑1 receptor agonists such as semaglutide and dual‑action agents like tirzepatide have shown significant liver‑fat reduction and histologic improvement. SGLT2 inhibitors and...
Eli Lilly to Sign $2bn Deal for AI Drug Development with Hong Kong Biotech
Eli Lilly has agreed to a roughly $2 billion partnership with a Hong Kong‑based biotech firm to develop new medicines using artificial‑intelligence platforms. The deal will give Lilly access to the startup’s AI‑driven discovery tools while providing the biotech with Lilly’s clinical expertise...
This New Therapy Turns Off Pain without Opioids or Addiction
Researchers at the University of Pennsylvania and collaborators have developed a preclinical gene therapy that selectively silences pain‑processing circuits in the brain, mimicking morphine’s analgesic effect without activating reward pathways. Using an AI‑driven system to map morphine‑responsive neurons in mice,...
Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE
New randomized data from the Ez‑PAVE trial in South Korea show that lowering LDL cholesterol to below 55 mg/dL in patients with established atherosclerotic cardiovascular disease reduces major cardiovascular events by 33% compared with a target of less than 70 mg/dL. The...
#AAD26: Biogen Declares Phase 2 Lupus Success for Anti-BDCA2 Antibody
Biogen announced positive Phase 2 results for litifilimab, its anti‑BDCA2 antibody targeting systemic lupus erythematosus. After 24 weeks, 14.7% of patients achieved complete clearance of skin lesions, meeting the trial’s primary endpoint. The data suggest the drug could become a...
KARDINAL: Monthly Tonlamarsen May Not Enhance BP Lowering in Resistant Hypertension
The phase II KARDINAL trial evaluated monthly versus single‑dose tonlamarsen, an angiotensinogen‑targeted nucleic‑acid therapy, in patients with resistant hypertension on multiple drugs. While monthly injections achieved a 67% reduction in plasma AGT compared with 23% after a single dose, both regimens...
Thousands of Americans Treated With Psilocybin in 2025
Psilocybin therapy is rapidly expanding across U.S. states, with Oregon reporting 5,935 patients in 2025 and Colorado opening its first regulated healing center. New Mexico is developing its own medical program while the federal government maintains prohibition. Scientific evidence shows...
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Takeda announced Phase 3 data for its oral TYK2 inhibitor, zasocitinib, showing rapid and durable skin clearance in moderate‑to‑severe plaque psoriasis. At week 16, 71% of patients achieved clear or almost clear skin (sPGA 0/1) versus roughly 10% on placebo and 30% on...
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Takeda announced that its oral TYK2 inhibitor zasocitinib delivered rapid and durable skin clearance in two global Phase 3 LATITUDE trials involving 693 and 1,108 moderate‑to‑severe plaque psoriasis patients. The drug met both co‑primary endpoints—sPGA 0/1 and PASI 75 at week 16—showing statistically significant...
Icotrokinra Delivers Complete Skin Clearance Through Week 52 With Strong Safety Profile: Linda Stein Gold, MD
FDA approval of icotrokinra introduces a new oral therapy for moderate‑to‑severe psoriasis. In the ICONIC‑ADVANCE trials, 100 % of patients achieved complete skin clearance through week 52, outperforming the oral benchmark deucravacitinib. The drug’s safety profile matched placebo, with fewer infections and...
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting,...
Biogen announced that litifilimab, an anti‑BDCA2 monoclonal antibody, achieved its primary endpoint in the Phase 2 portion of the AMETHYST study for cutaneous lupus erythematosus (CLE). The drug showed an 11.8% greater reduction in disease activity versus placebo, with 14.7% of...
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Priovant Therapeutics announced that its TYK2/JAK1 inhibitor brepocitinib met the primary endpoint in the Phase 3 VALOR trial for dermatomyositis, showing a 15.3‑point improvement in Total Improvement Score at week 52 versus placebo. The 30 mg dose also delivered significant steroid‑sparing effects, with...
Real-World Patterns of Peri-Procedural Antiplatelet Therapy and Concomitant Verapamil Use During Transradial Percutaneous Coronary Intervention
A single‑center retrospective study of 204 transradial PCI cases (2024‑25) found verapamil used in 98.5% of procedures. Ticagrelor was administered in 33.3% of cases, and 97.1% of ticagrelor patients also received verapamil, yielding an overall co‑exposure rate of 32.4%. Ticagrelor...
#AAD26: Tanabe’s Phase 3 Win for Drug Targeting Rare Diseases that Cause Pain upon Light Exposure
Tanabe Pharma announced that its oral investigational drug achieved positive results in a pivotal Phase 3 trial for erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP), two ultra‑rare phototoxic disorders. The study met its primary endpoint of reducing light‑induced pain episodes and...
Adjuvant Pembrolizumab Maintains Benefit-Risk Profile for High-Risk Stage II Melanoma in KEYNOTE-716 Analysis
Adjuvant pembrolizumab (Keytruda) continued to show a strong recurrence‑free survival (RFS) advantage in resected stage IIB/IIC melanoma, with median RFS not reached versus 59.2 months for placebo (hazard ratio 0.65). The 48‑month RFS rates were 68.7% with pembrolizumab compared with...
Efficacy and Potential Pharmacological Mechanisms of Total Glucosides of Paeony in Treating Ankylosing Spondylitis in Asian Populations: A Meta-Analysis, Network...
A meta‑analysis of 28 randomized trials involving 2,130 Asian patients shows that total glucosides of paeony (TGP) combined with conventional therapy significantly improves spinal function, reduces inflammatory markers such as ESR and CRP, and enhances quality‑of‑life scores in ankylosing spondylitis...
Cell and Gene Therapy Manufacturing Exposes the Cost of Delayed Digital Infrastructure
Cell and gene therapy (CGT) manufacturing is advancing quickly, yet many early‑stage firms postpone building an integrated digital backbone. The resulting manual handoffs create safety, compliance, and scalability risks. SAP’s Cell and Gene Therapy Orchestration platform introduces guided workflows, e‑signatures,...